David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X:
“Healthy discussion on the success of EV based perioperative therapy – every patient with MIBC should have a consult with medical oncology to discuss risks and benefits of therapy.”
You can also read:
- EV-303/KEYNOTE-905 Trial: CHMP Supports PADCEV + Pembrolizumab in Cisplatin-Ineligible MIBC
- FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer
